SNAP-8: Zero PubMed Records, and 2.2× the 500-Dalton Skin Penetration Threshold

SNAP-8 is sold as a needle-free botox with wrinkle-reduction percentages attached to it. PubMed returns zero records for the compound under either of its names. Every one of those percentages comes from supplier marketing material, not peer review.

That is unusual even in this market, where thin evidence is normal and no evidence is rare. Identity and vendor listings sit on the SNAP-8 compound page, within the skin and anti-aging peptides category, and the compound's molecular weight creates a second problem before efficacy is even reached.

What does PubMed return for SNAP-8?

Nothing. A PubMed search for "SNAP-8" in titles and abstracts returns count = 0, and the database explicitly reports the phrase as not found. Searching "acetyl octapeptide" instead returns count = 0 with the same message. Both of SNAP-8's names are absent from the world's largest biomedical index, which means every wrinkle-reduction percentage attached to this ingredient comes from supplier marketing material rather than peer review.

Not few results. Zero, twice, under both names the compound trades under.

Could that be a search error?

No, and we checked rather than assumed. We ran a combined search across SNAP-8, acetyl octapeptide, Argireline and acetyl hexapeptide, which returned 49 records — and PubMed's own query translation shows the database silently discarded both SNAP-8 terms, because neither matches anything it holds. All 49 records belong to Argireline, the six-residue peptide SNAP-8 is an extension of. SNAP-8 contributed none of them.

That last detail is the one worth keeping. A search engine that quietly drops an unmatched term will still return results, and a reader who does not open the query translation will conclude the compound has a literature. It does not.

Can a 1,075-dalton peptide cross skin?

SNAP-8 is 1,075.2 Da, which is 2.2 times the 500-dalton threshold Bos and Meinardi (Experimental Dermatology 2000;9(3):165–169, PMID 10839713) proposed as a practical upper limit for compounds crossing intact stratum corneum. No penetration study of SNAP-8 has been published in either direction. GHK-Cu at around 403 Da clears the threshold and Argireline at ~889 Da is 1.8 times over it. The size problem therefore sits ahead of the efficacy problem.

The paper's title is "The 500 Dalton rule for the skin penetration of chemical compounds and drugs," and the number in it is the reason cosmetic chemistry cares about peptide size at all.

Is the 500-dalton rule a law?

No, and that matters for fairness to SNAP-8. Bos and Meinardi framed 500 daltons as a rule of thumb rather than a law, and published counterexamples exist — a 2005 paper in Bioorganic & Medicinal Chemistry describes cyclosporin derivatives with enhanced skin penetration despite increased molecular weight. The threshold is a strong prior, not proof of zero penetration. A strong prior against penetration plus zero published penetration data and zero published efficacy data is still a meaningfully worse position.

Worse, specifically, than most cosmetic peptides occupy. GHK-Cu at least clears the size threshold, which means its topical delivery question is open rather than argued uphill. SNAP-8 has to overcome the prior and has published nothing that attempts to.

Is the SNARE mechanism plausible?

The rationale is coherent and untested. SNAP-8's sequence derives from the N-terminus of SNAP-25, a component of the SNARE complex that mediates neurotransmitter vesicle fusion, and the proposal is that the peptide competes with SNAP-25 for SNARE assembly, reducing acetylcholine release at the neuromuscular junction. Botulinum toxin works by cleaving SNAP-25, so the target is not absurd. Whether this happens in human skin has never been tested in peer-reviewed literature.

That is the claimed mechanism: real pharmacology applied to an unrealistic setting. Interfering with a complex that botulinum toxin also targets is a legitimate idea, and someone had it, made the molecule and put it into cosmetics.

The untested part is not a gap in the evidence. It is the absence of an evidence base, because there is no peer-reviewed literature on this compound at all — which means nobody has published whether the competition happens, at what concentration it would need to happen, or whether that concentration is reachable through skin.

What is SNAP-8 chemically?

SNAP-8 is Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂, an eight-residue peptide with both termini blocked, CAS 868844-74-0, formula C₄₁H₇₀N₁₆O₁₆S and a molecular weight of 1,075.2 g/mol. Its INCI name is acetyl octapeptide-3. We confirmed the capping by mass balance: building the formula from the EEMQRRAD residue composition and adding an acetyl cap and an amide cap reproduces PubChem's formula and 1,075.17 exactly. SNAP-8 minus Argireline is 186.17 Da, exactly alanine plus aspartate.

The 186.17 Da figure is precisely the alanine residue (71.079) plus the aspartate residue (115.089). The arithmetic closes to the decimal, which is strong internal confirmation that the elongation description is correct — and it is also the number that makes the two compounds trivially separable by mass spectrometry.

Which PubChem record is SNAP-8?

There are two, and no single unambiguous reference record exists. CAS 868844-74-0 returns PubChem CID 76283482, formula C₄₁H₇₀N₁₆O₁₆S, and also CID 71587832, which is likewise titled "Acetyl octapeptide-3" but carries a different formula, C₄₂H₇₂N₁₆O₁₅S. Two structures, one CAS number, one INCI name. Anyone verifying SNAP-8 identity against a database needs to know which record they are checking against before the comparison means anything.

This is a different failure from a vendor typing the wrong number. The ambiguity is upstream, in the reference layer itself, which means two honest parties can check the same certificate against the same CAS and disagree about what the correct formula is.

How does SNAP-8 compare with Argireline?

Argireline has 49 indexed PubMed papers and two registered clinical trials; SNAP-8 has zero of both. Argireline is Ac-EEMQRR-NH₂ and SNAP-8 adds Ala-Asp at the C-terminus, a difference of 186.17 Da — precisely alanine at 71.079 plus aspartate at 115.089. The registered Argireline work is NCT01750346, "Acetyl Hexapeptide-8 for Blepharospasm," terminated, and NCT00942851, completed. Neither of those trials studied SNAP-8, and Argireline remains the cheaper and more widely available of the two.

So the predecessor has been through registered clinical work, one arm of which was terminated, and the elongated version has not. The two-residue extension is what SNAP-8 is sold on; no published study compares them.

Is there any safety data for injected SNAP-8?

None of any kind. ClinicalTrials.gov returns totalCount = 0 for SNAP-8 and totalCount = 0 for acetyl octapeptide — no trials, no PubMed records, nothing. Our price data shows it sold in vials up to 1,000 mg, which is a bulk cosmetic raw-material presentation rather than a unit-dose injection format. We could not survey vendor marketing directly, so we are not asserting how it is being promoted.

What we can say is that no published safety information exists for administering this compound by any route other than topical. A gram-scale vial is a formulation input, and treating it as anything else means acting entirely outside any published record.

Does "not FDA-approved" mean anything for a cosmetic ingredient?

No. FDA states that "the law does not require cosmetic products and ingredients, other than color additives, to have FDA approval before they go on the market," so the phrase carries no information about SNAP-8 — nothing in a face cream is FDA-approved. The more interesting boundary is the one FDA draws next, between a cosmetic effect on appearance and a claim to affect the structure or function of the body.

FDA's second statement, verbatim:

"If the product is intended for a therapeutic use, such as treating or preventing disease, or to affect the structure or function of the body, it's a drug... even if it affects the appearance."

A claim that a product blocks nerve signals to muscle is a structure-function claim. It describes a pharmacological action on the body, not a cosmetic effect on appearance. That is precisely the line FDA describes, and it is the line the "needle-free botox" framing walks up to.

We are not asserting that any specific product has crossed it — that is a determination for FDA, and there is no FDA position specific to SNAP-8 that we could locate. SNAP-8 and acetyl octapeptide do not appear anywhere on FDA's compounding pages.

On WADA: SNAP-8, acetyl octapeptide and Argireline do not appear anywhere in the 2026 Prohibited List. Of the compounds in this cosmetic group, a topical SNAP-8 preparation is the weakest candidate for capture by the S0 catch-all, since a topical cosmetic is not obviously a pharmacological substance for human therapeutic use. See our FDA peptide regulation timeline.

What does Peptigrity's platform data show for SNAP-8?

The Purity Index records SNAP-8 at 99.38% average across 74 independent HPLC tests (verified May 2026), from Ethos Analytics, ILS, Kovera, Freedom Diagnostics, Janoshik and Vanguard, across 223 verified vendors, with one test on 13 June 2026 returning 96.14%. The notable finding is not purity but fill: weight variance runs from 0% to +30.3% against label, on a product sold in gram-scale vials as a raw material.

A 30% overage is not a bonus and it is not a rounding issue. It means fill quantity is not controlled at that vendor, and a process that overfills by a third will underfill by a similar margin on other batches. On a raw material, that variance compounds through whatever formulation it goes into, which is the problem set out in why 10 mg isn't 10 mg.

SNAP-8 price data shows 35 shops in stock, median $3.50/mg, lowest $0.20/mg on a 1,000 mg vial (verified 11 August 2026). Those figures exclude shipping, taxes and customs, coupon codes, bulk tiers, multi-vial kits and account-gated pricing.

Note the seventeen-fold spread between the median and the floor price, driven entirely by vial size. A one-gram vial is a bulk cosmetic raw-material format; a milligram-scale vial is a consumer presentation. They are not competing offers for the same thing, and comparing them on price per milligram is comparing two different products.

Peptigrity tracks 530 shops and 11,852 independent lab tests across 118 peptides, with 1,283 community reviews (verified August 2026). Trust scores weight community reviews and independently verified HPLC purity equally, at 50% each. Certificates sit in the lab test database and vendor rankings in community-verified shop reviews.

How do you verify a SNAP-8 vial?

Mass spectrometry, reading 1,075.2 Da with both terminal caps intact rather than Argireline at ~889 Da. The two compounds are 186 Da apart, which is a large and obvious gap on a mass spectrum and completely invisible on a purity certificate. Also confirm both caps are present, because an uncapped peptide is a different molecule that degrades faster, and check fill accuracy against label given the +30.3% variance on record.

The Argireline check is the practical one, because Argireline is cheaper and more widely available, and substituting it would leave a purity certificate looking perfect. What mass spectrometry for peptides resolves in one reading, HPLC cannot address at all.

Which SNAP-8 claims survive the evidence?

None of the eight. Wrinkle-depth percentages are unsupported by literature because there is none; "clinically proven" is false against PubMed count = 0 and ClinicalTrials.gov count = 0; SNARE competition is a hypothesis never tested in human skin; skin penetration is doubtful and untested at 2.2 times the 500 Da rule; injection safety is unknown; and "not FDA-approved" is a misunderstood claim for a cosmetic ingredient.

Only one of those eight verdicts could move on new evidence in a single step. Publishing one credible penetration study would convert "Doubtful, untested" into an answer either way, and every other row depends on that answer.

Frequently Asked Questions

Is SNAP-8 clinically proven?

No. PubMed returns zero records for both "SNAP-8" and "acetyl octapeptide" in titles and abstracts — the database explicitly reports both phrases as not found. ClinicalTrials.gov returns zero registered studies. Every efficacy figure in circulation comes from supplier marketing material.

What about Argireline?

Argireline — acetyl hexapeptide-8 — has 49 indexed PubMed records and two registered clinical trials, one of which was terminated. SNAP-8 is Argireline elongated by two residues, and has neither.

Can SNAP-8 penetrate skin?

Unknown and doubtful. At 1,075.2 Da it is 2.2 times the 500-dalton threshold Bos and Meinardi proposed as a practical limit for skin penetration. That rule is a heuristic with published counterexamples, not a law — but no penetration study of SNAP-8 has been published in either direction.

Is the SNARE mechanism real?

The rationale is coherent: the sequence derives from SNAP-25, and botulinum toxin works by cleaving SNAP-25. Whether SNAP-8 actually competes for SNARE assembly in human skin at topically achievable concentrations has never been tested in published literature.

Is SNAP-8 FDA-approved?

Cosmetic ingredients do not require FDA approval before marketing — FDA states this explicitly. There is no FDA position specific to SNAP-8, and it does not appear on any FDA compounding list. Note FDA's boundary: a product intended "to affect the structure or function of the body" is regulated as a drug even if it affects appearance.

Can I inject it?

No safety data exists for injected SNAP-8 — no trials, no case reports, no published pharmacology in humans by any route other than topical.

The trial that would settle this

The trial that would settle SNAP-8 begins with a penetration study, because everything downstream depends on whether 1,075 Da crosses intact stratum corneum and at what concentration. After that: randomised, vehicle-controlled, split-face design, objective 3D wrinkle imaging as a pre-specified endpoint, Argireline as the comparator, 12 weeks minimum, and publication in a peer-reviewed indexed journal. The current evidence base is zero indexed records.

The first row is the honest gate. If a 1,075 Da peptide does not reach the neuromuscular junction beneath the dermis in meaningful quantity, no efficacy trial will produce a signal, and no supplier percentage explains how it got past the stratum corneum.

Where this leaves SNAP-8

SNAP-8 is the emptiest file on this platform, and unusually the emptiness is easy to verify: two PubMed searches returning zero, and a third confirming the database discarded the terms because nothing matches them. The mechanism is not absurd — SNAP-25 is a real target and botulinum toxin proves the pathway matters. What did not follow was any published test of whether it works, whether it penetrates, or whether SNARE competition happens in skin.

The predecessor molecule has 49 papers and two registered trials. This one has a supplier brochure.

Meanwhile the material sells at a 17-fold price spread depending on vial size, with fill quantities running up to 30% over label, into formulations where the buyer has no way to check what arrived except a purity percentage that cannot distinguish it from the cheaper compound it was derived from.

Browse the skin and anti-aging peptides category, or our complete peptide guide with 118 compounds (verified August 2026). Compare shops through independent lab tests and community-verified shop reviews.

This article is for educational and informational purposes only and does not constitute medical advice. Peptides discussed may be investigational compounds not approved by the FDA (or equivalent regulators in your jurisdiction) for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.